Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BPM31510 in Healthy Subjects
NCT02486055Phase 1Completed
- Sponsor
- BPGbio
- Start
- Nov 2015
- Primary completion
- Jan 2016
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPM31510-Oral in glioblastoma multiforme (GBM) and pancreatic cancer (PC) (3 cohorts), sponsored by BPGbio. Primary endpoint: Maximum Plasma Concentration at Day 15. Started Nov 2015; status: completed.
02
Drugs
BPM31510-Oral
03
Conditions
glioblastoma multiforme (GBM)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02486055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486055.